- Home
- IP vs RPRX Comparison
IP vs RPRX Comparison
Compare IP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IP | RPRX |
|---|---|---|
| Founded | 1898 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IP | RPRX |
|---|---|---|
| Price | $34.20 | $45.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $48.50 | $47.75 |
| AVG Volume (30 Days) | ★ 5.2M | 2.7M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.15% | 2.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $7.71 | $38.30 |
| Revenue Next Year | $3.88 | $4.80 |
| P/E Ratio | ★ N/A | $25.81 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $35.45 | $29.66 |
| 52 Week High | $56.64 | $47.86 |
Technical Indicators
Market Signals| Indicator | IP | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.42 | 53.62 |
| Support Level | N/A | $44.94 |
| Resistance Level | $39.52 | $46.14 |
| Average True Range (ATR) | 1.51 | 0.86 |
| MACD | -0.64 | -0.24 |
| Stochastic Oscillator | 5.47 | 23.80 |
Price Performance
Historical ComparisonAbout IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.